SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Nuwellis, Inc. (NUWE) (CIK 0001506492) (NUWE) — Dec 27, 2019

Nuwellis, Inc. (NUWE) (CIK 0001506492)
Date: Dec. 27, 2019 · CIK: 0001506492 · Accession: 0000000000-19-016810

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-235658

Date
December 27, 2019
Author
Irene Paik
Form
UPLOAD
Company
Nuwellis, Inc. (NUWE) (CIK 0001506492)

Letter

December 27, 2019 John Erb Chief Executive Officer CHF Solutions, Inc. 12988 Valley View Road Eden Prairie, Minnesota 55344 Re:CHF Solutions, Inc. Registration Statement on Form S-1 Filed December 20, 2019 File No. 333-235658 Dear Mr. Erb: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Phillip Torrence, Esq.

Show Raw Text
December 27, 2019
John Erb
Chief Executive Officer
CHF Solutions, Inc.
12988 Valley View Road
Eden Prairie, Minnesota 55344
Re:CHF Solutions, Inc.
Registration Statement on Form S-1
Filed December 20, 2019
File No. 333-235658
Dear Mr. Erb:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Phillip Torrence, Esq.